RESUMEN
BACKGROUND: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibitors, recently approved for various ages in this indication. OBJECTIVES: This expert consensus aimed to provide practical recommendations within this advancing field to enhance clinical decision-making on the use of these and other systemics for children and adolescents aged ≥2 years with moderate-to-severe AD. METHODS: Nineteen physicians from Northern Europe were selected for their expertise in managing childhood AD. Using a two-round Delphi process, they reached full or partial consensus on 37 statements. RESULTS: Systemic therapy is recommended for children aged ≥2 years with a clear clinical diagnosis of severe AD and persistent disease uncontrolled after optimizing non-systemic therapy. Systemic therapy should achieve long-term disease control and reduce short-term interventions. Recommended are cyclosporine A for short-term use (all ages) and dupilumab or methotrexate for long-term use (ages ≥6 years). Consensus was not reached on the best long-term systemics for children aged 2-6 years, although new systemic therapies will likely become favourable: New biologics and JAK inhibitors will soon be approved for this age group, and more trial and real-world data will become available. CONCLUSIONS: This article makes practical recommendations on the use of systemic AD treatments for children and adolescents, to supplement international and regional guidelines. It considers the systemic medication that was available for children and adolescents with moderate-to-severe AD at the time this consensus project was done: azathioprine, cyclosporine A, dupilumab, methotrexate, mycophenolate mofetil and oral glucocorticosteroids. We focus on the geographically similar Northern European countries, whose healthcare systems, local preferences for AD management and reimbursement structures nonetheless differ significantly.
Asunto(s)
Productos Biológicos , Dermatitis Atópica , Inhibidores de las Cinasas Janus , Adolescente , Azatioprina/uso terapéutico , Productos Biológicos/uso terapéutico , Niño , Preescolar , Ciclosporina/uso terapéutico , Técnica Delphi , Dermatitis Atópica/terapia , Testimonio de Experto , Humanos , Inhibidores de las Cinasas Janus/uso terapéutico , Quinasas Janus , Metotrexato/uso terapéutico , Ácido Micofenólico/uso terapéutico , Calidad de VidaRESUMEN
BACKGROUND: Bullous pemphigoid (BP), the by far most frequent autoimmune blistering skin disease (AIBD), is immunopathologically characterized by autoantibodies against the two hemidesmosomal proteins BP180 (collagen type XVII) and BP230 (BPAG1 or dystonin). Several comorbidities and potentially disease-inducing medication have been described in BP, yet a systematic analysis of these clinically relevant findings and autoantibody reactivities has not been performed. OBJECTIVE: To determine associations of autoantibody reactivities with comorbidities and concomitant medication. METHODS: In this prospective multicenter study, 499 patients diagnosed with BP in 16 European referral centers were included. The relation between anti-BP180 NC16A and anti-BP230 IgG ELISA values at the time of diagnosis as well as comorbidities and concomitant medication collected by a standardized form were analysed. RESULTS: An association between higher serum anti-BP180 reactivity and neuropsychiatric but not atopic and metabolic disorders was observed as well as with the use of insulin or antipsychotics but not with dipeptidyl peptidase-4 (DPP4) inhibitors, inhibitors of platelet aggregation and L-thyroxine. The use of DPP4 inhibitors was associated with less anti-BP180 and anti-BP230 reactivity compared with BP patients without these drugs. This finding was even more pronounced when compared with diabetic BP patients without DPP4 inhibitors. Associations between anti-BP180 and anti-BP230 reactivities were also found in patients using insulin and antipsychotics, respectively, compared with patients without this medication, but not for the use of inhibitors of platelet aggregation, and L-thyroxine. CONCLUSION: Taken together, these data imply a relation between autoantibody reactivities at the time of diagnosis and both neuropsychiatric comorbidities as well as distinct concomitant medication suggesting a link between the pathological immune mechanisms and clinical conditions that precede the clinically overt AIBD.
Asunto(s)
Antipsicóticos , Inhibidores de la Dipeptidil-Peptidasa IV , Insulinas , Penfigoide Ampolloso , Enfermedad del Suero , Antipsicóticos/efectos adversos , Autoanticuerpos , Autoantígenos , Vesícula , Dipeptidil Peptidasa 4/uso terapéutico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Distonina , Humanos , Hipoglucemiantes/uso terapéutico , Inmunoglobulina G , Insulinas/uso terapéutico , Colágenos no Fibrilares , Estudios Prospectivos , Tiroxina/uso terapéuticoAsunto(s)
Hidradenitis Supurativa/epidemiología , Esperanza de Vida , Mortalidad/tendencias , Factores de Edad , Anciano , Estudios de Casos y Controles , Comorbilidad , Femenino , Finlandia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Sistema de Registros/estadística & datos numéricos , Medición de RiesgoAsunto(s)
Fosfatidilinositol 3-Quinasa Clase Ia/metabolismo , Inhibidores Enzimáticos/efectos adversos , Purinas/efectos adversos , Quinazolinonas/efectos adversos , Piel/efectos de los fármacos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Inhibidores Enzimáticos/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Purinas/metabolismo , Quinazolinonas/metabolismoRESUMEN
WHAT IS KNOWN AND OBJECTIVE: Calciphylaxis is a rare and potentially life-threatening cause of skin necrosis and is poorly recognized by clinicians in non-uraemic patients. CASE DESCRIPTION: We report five cases of warfarin-induced calciphylaxis in patients with normal renal function. In four cases, sodium thiosulphate was successfully used as a treatment. No other predisposing factors besides obesity and warfarin were found in these patients. WHAT IS NEW AND CONCLUSION: Previously only few cases of solely warfarin-induced calciphylaxis have been described. Treatment with sodium thiosulphate has shown promising results, and there is thus a need to improve the recognition of calciphylaxis.
RESUMEN
BACKGROUND: Allergic contact dermatitis caused by wood dust remains uncommon and most cases are occupational. Contact allergy to finished wooden products is even more rare and only few cases of contact dermatitis to wooden furnishings and furniture are described. OBJECTIVE: During 2012-2014 surprisingly many patients with dermatitis associated to sauna baths were referred to our clinic. METHODS: We report three novel cases with allergic contact dermatitis to western red cedar due to exposure during sauna baths. RESULTS: Three cases of non-occupational contact dermatitis to western red cedar were confirmed by patch testing. CONCLUSION: Allergic contact dermatitis to interior decoration or furniture is a rarity, but can be induced by novel exposures, like western red cedar in sauna interior decoration.